原发性醛固酮增多症的心血管损害研究进展

doi:10.16138/j.1673-6087.2023.04.019

摘要/Abstract

中图分类号:

R586.24

柯钰雅, 龚艳春. 原发性醛固酮增多症的心血管损害研究进展[J]. 内科理论与实践, 2023, 18(04): 301-304.

KE Yuya, GONG Yanchun. Research progress of cardiovascular damage in primary aldosteronism[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 301-304.

参考文献 36

[1]	Haze T, Hirawa N, Yano Y, et al. Association of aldo-sterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism[J]. Atherosclerosis, 2021, 324: 84-90. doi: 10.1016/j.atherosclerosis.2021.03.033 URL
[2]	Hundemer GL, Vaidya A. Primary aldosteronism diagnosis and management[J]. Endocrinol Metab Clin North Am, 2019, 48(4): 681-700. doi: 10.1016/j.ecl.2019.08.002 URL
[3]	Monticone S, Sconfienza E, D’Ascenzo F, et al. Renal damage in primary aldosteronism: a systematic review and meta-analysis[J]. J Hypertens, 2020, 38(1): 3-12. doi: 10.1097/HJH.0000000000002216 pmid: 31385870
[4]	Conn JW, Louis LH. Primary aldosteronism, a new clinical entity[J]. Ann Intern Med, 1956, 44(1): 1-15. doi: 10.7326/0003-4819-44-1-1 pmid: 13275846
[5]	Cheng CJ, Sung CC, Wu ST, et al. Novel KCNJ5 mutations in sporadic aldosterone-producing adenoma reduce Kir3.4 membrane abundance[J]. J Clin Endocrinol Metab, 2015, 100(1): E155-E163. doi: 10.1210/jc.2014-3009 URL
[6]	Fernandes-Rosa FL, Daniil G, Orozco IJ, et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism[J]. Nat Genet, 2018, 50(3): 355-361. doi: 10.1038/s41588-018-0053-8 pmid: 29403012
[7]	Perez-Rivas LG, Williams TA, Reincke M. Inherited forms of primary hyperaldosteronism: new genes, new phenotypes and proposition of a new classification[J]. Exp Clin Endocrinol Diabetes, 2019, 127(2/3): 93-99. doi: 10.1055/a-0713-0629 URL
[8]	Daniil G, Fernandes-Rosa FL, Chemin J, et al. CACNA1H mutations are associated with different forms of primary aldosteronism[J]. EBioMedicine, 2016, 13: 225-236. doi: 10.1016/j.ebiom.2016.10.002 URL
[9]	Fernandes-Rosa FL, Giscos-Douriez I, Amar L, et al. Different somatic mutations in multinodular adrenals with aldosterone-producing adenoma[J]. Hypertension, 2015, 66(5): 1014-1022. doi: 10.1161/HYPERTENSIONAHA.115.05993 pmid: 26351028
[10]	Nishimoto K, Tomlins SA, Kuick R, et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands[J]. Proc Natl Acad Sci U S A, 2015, 112(33): E4591-E4599.
[11]	Wannachalee T, Turcu AF. Primary aldosteronism: a continuum from normotension to hypertension[J]. Curr Cardiol Rep, 2021, 23(8): 105. doi: 10.1007/s11886-021-01538-8 pmid: 34196827
[12]	Abdel Ghafar MT. An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension[J]. Steroids, 2020, 163: 108701. doi: 10.1016/j.steroids.2020.108701 URL
[13]	Gao X, Yamazaki Y, Tezuka Y, et al. Pathology of aldo-sterone biosynthesis and its action[J]. Tohoku J Exp Med, 2021, 254(1): 1-15. doi: 10.1620/tjem.254.1 URL
[14]	van der Heijden CDCC, Smeets EMM, Aarntzen EHJG, et al. Arterial wall inflammation and increased hematopoietic activity in patients with primary aldosteronism[J]. J Clin Endocrinol Metab, 2020, 105(5): E1967-E1980. doi: 10.1210/clinem/dgz306 URL
[15]	Rossi GP, Maiolino G. Excess arterial damage in hyperaldosteronism[J]. Hypertension, 2019, 74 (3): 502-504. doi: 10.1161/HYPERTENSIONAHA.119.12395 pmid: 31352816
[16]	Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldo-steronism compared with essential hypertension: a systematic review and meta-analysis[J]. Lancet Diabetes Endocrinol, 2018, 6(1): 41-50. doi: 10.1016/S2213-8587(17)30319-4 URL
[17]	Ohno Y, Sone M, Inagaki N, et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism[J]. Hypertension, 2018, 71(3): 530-537. doi: 10.1161/HYPERTENSIONAHA.117.10263 URL
[18]	Sukor N. Primary aldosteronism: from bench to bedside[J]. Endocrine, 2012, 41(1): 31-39. doi: 10.1007/s12020-011-9553-3 pmid: 22042487
[19]	Meng Z, Dai Z, Huang K, et al. Long-term mortality for patients of primary aldosteronism compared with essential hypertension[J]. Front Endocrinol (Lausanne), 2020, 11: 121. doi: 10.3389/fendo.2020.00121 URL
[20]	Andrea Grillo, Lucia Salvi, Coruzzi P, et al. Sodium intake and hypertension[J]. Nutrients, 2019, 11(9): 1970. doi: 10.3390/nu11091970 URL
[21]	Kronenberg H, Melmed S, Polonsky K, et al. Williams textbook of endocrinology[M]. 11th ed. Philadelphia, PA: Saunders, 2007: 1452-1463.
[22]	Sang M, Fu Y, Wei C, et al. Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension[J]. J Renin Angiotensin Aldosterone Syst, 2021, 22(1): 1470320321999491.
[23]	Concistrè A, Petramala L, Bonvicini M, et al. Comparisons of skin microvascular changes in patients with primary aldosteronism and essential hypertension[J]. Hypertens Res, 2020, 43(11): 1222-1230. doi: 10.1038/s41440-020-0475-4
[24]	Lottspeich C, Köhler A, Czihal M, et al. Atherosclerotic burden and arterial stiffness are not increased in patients with milder forms of primary aldosteronism compared to patients with essential hypertension[J]. Horm Metab Res, 2021, 53(3): 178-184. doi: 10.1055/a-1326-2164 pmid: 33440431
[25]	Choudhary MK, Värri E, Matikainen N, et al. Primary aldosteronism: higher volume load, cardiac output and arterial stiffness than in essential hypertension[J]. J Intern Med, 2021, 289(1): 29-41. doi: 10.1111/joim.v289.1 URL
[26]	Pimenta E, Gordon RD, Ahmed AH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism[J]. J Clin Endocrinol Metab, 2011, 96(9): 2813-2820. doi: 10.1210/jc.2011-0354 URL
[27]	Huang X, Yu S, Xiao H, et al. Comparison of clinical features between primary aldosteronism and essential hypertension in Chinese patients[J]. Int J Endocrinol, 2021, 2021: 6685469.
[28]	Wu Q, Hong M, Xu J, et al. Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism[J]. Endocrine, 2021, 72(3): 835-843. doi: 10.1007/s12020-021-02606-3 pmid: 33474712
[29]	Wachtel H, Cerullo I, Bartlett EK, et al. Long-term blood pressure control in patients undergoing adrenalectomy for primary hyperaldosteronism[J]. Surgery, 2014, 156(6): 1394-1402. doi: 10.1016/j.surg.2014.08.021 URL
[30]	Ahmed S, Hundemer GL. Benefits of surgical over medical treatment for unilateral primary aldosteronism[J]. Front Endocrinol (Lausanne), 2022, 13: 861581. doi: 10.3389/fendo.2022.861581 URL
[31]	Satoh F, Ito S, Itoh H, et al. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism[J]. Hypertens Res, 2020, 44(4): 464-472. doi: 10.1038/s41440-020-00570-5
[32]	Rakugi H, Ito S, Itoh H, et al. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension[J]. Hypertens Res, 2019, 42(12): 1932-1941. doi: 10.1038/s41440-019-0314-7 pmid: 31554937
[33]	Ravid JD, Laffin LJ. Effects of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular disease, chronic kidney disease, and blood pressure[J]. Curr Cardiol Rep, 2022, 24(10): 1251-1259. doi: 10.1007/s11886-022-01750-0 pmid: 35925515
[34]	Hundemer GL, Curhan GC, Yozamp N, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism[J]. Lancet Diabetes Endocrinol, 2018, 6(1): 51-59. doi: 10.1016/S2213-8587(17)30367-4 URL
[35]	Nomura M, Kurihara I, Itoh H, et al. Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism[J]. Hypertens Res, 2022, 45(9): 1476-1485. doi: 10.1038/s41440-022-00960-x
[36]	Kallistratos MS, Pittaras A, Theodoulidis I, et al. Adverse effects of mineralocorticoid receptor antagonist administration[J]. Curr Pharm Des, 2018, 24(46): 5537-5541. doi: 10.2174/1381612825666190222144359 URL

原发性醛固酮增多症的心血管损害研究进展

Research progress of cardiovascular damage in primary aldosteronism

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 15

编辑推荐

Metrics

本文评价

[1]	蒋怡然, 王卫庆. 原发性醛固酮增多症的分子机制研究进展[J]. 内科理论与实践, 2023, 18(04): 261-265.
[2]	施仲伟. 从学术角度看高血压诊断界值不应下调至130/80 mmHg[J]. 诊断学理论与实践, 2023, 22(04): 348-361.
[3]	赖莉琴, 龚艳春. 原发性醛固酮增多症慢性肾损伤的研究进展[J]. 内科理论与实践, 2023, 18(03): 211-214.
[4]	钱莹, 马晓波, 高琛妮, 张春丽, 马骏, 张文, 陈晓农. 慢性肾脏病患者高尿酸血症与高血压的关联分析[J]. 诊断学理论与实践, 2023, 22(02): 160-165.
[5]	李歆旎, 马文坤, 高程洁, 高亚洁, 金雪娟, 周翌, 沈成兴, 潘静薇. 不同诊断标准对人群高血压患病率的影响[J]. 内科理论与实践, 2022, 17(04): 273-277.
[6]	杨洋, 龚艳春. 无症状高尿酸血症与心血管疾病和肾脏疾病关系的研究进展[J]. 内科理论与实践, 2021, 16(05): 366-370.
[7]	李倩倩, 辛晓瑜, 汤荟冬, 吴方. 急性脑梗死住院患者脑白质疏松症的发生率及其影响因素分析[J]. 内科理论与实践, 2021, 16(04): 240-245.
[8]	杨扬, 吴琴咪, 冯玉兰, 张蓓, 傅毅. 高血压患者脑血管周围间隙扩大和脑腔隙灶相关影响因素[J]. 诊断学理论与实践, 2021, 20(04): 372-377.
[9]	中国高血压联盟《动态血压监测指南》委员会. 2020中国动态血压监测指南[J]. 诊断学理论与实践, 2021, 20(01): 21-36.
[10]	蒋怡然, 王卫庆. 原发性醛固酮增多症的诊治现状及展望[J]. 诊断学理论与实践, 2020, 19(05): 445-449.
[11]	陈歆, 程艾邦, 许建忠, 李燕, 王继光. 中国高血压患者原发性醛固酮增多症的前瞻性筛查研究进展[J]. 诊断学理论与实践, 2020, 19(05): 450-453.
[12]	中国高血压联盟. 高血压患者原发性醛固酮增多症筛查诊治流程[J]. 诊断学理论与实践, 2020, 19(05): 454-459.
[13]	程艾邦, 李明轩, 陈波, 曹晟, 蒋塨豪, 许建忠, 李燕, 王继光. 化学发光免疫分析法检测血浆肾素、醛固酮在原发性醛固酮增多症诊断中的价值[J]. 诊断学理论与实践, 2020, 19(05): 474-480.
[14]	李宙童, 张炜, 王继光. 家庭血压测量诊断白大衣高血压及隐匿性高血压的准确性研究[J]. 诊断学理论与实践, 2020, 19(05): 487-493.
[15]	胡哲, 陈歆, 罗芳秀, 初少莉, 王继光. 肾上腺醛固酮和皮质醇共分泌瘤一例报告[J]. 诊断学理论与实践, 2020, 19(05): 525-527.